RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+15.44%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$855M
AUM Growth
+$855M
(-2.3%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-12.86%
Top 10 Holdings %
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
18
Reduced
37
Closed
8
Top Buys
| 1 |
LivaNova
LIVN
|
$11.7M |
| 2 |
Exact Sciences
EXAS
|
$8.66M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$7.76M |
| 4 |
MacroGenics
MGNX
|
$7.64M |
| 5 |
Nektar Therapeutics
NKTR
|
$7.37M |
Top Sells
| 1 |
Biogen
BIIB
|
$18.1M |
| 2 |
Incyte
INCY
|
$14.3M |
| 3 |
CELG
Celgene Corp
CELG
|
$14.2M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$13.6M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.7M |
Sector Composition
| 1 | Healthcare | 93.64% |
| 2 | Technology | 0.15% |
| 3 | Energy | 0.14% |
| 4 | Financials | 0.1% |
| 5 | Communication Services | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
Biogen
BIIB
$20.8B
| – | – |
-60,000
| Closed | -$18.1M |
|